

Printed on: Fri May 13 2022 09:19:58 GMT-0400 (Eastern Daylight Time)

| BLA Number | Applicant Name | Proprietary Name | Proper Name   | Patent Number | Patent |
|------------|----------------|------------------|---------------|---------------|--------|
| 125031     | Amgen, Inc.    | Neulasta         | pegfilgrastim | 9,856,287     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 6,805,686     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,231,876     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,420,081     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,663,945     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,708,968     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,715,664     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,808,700     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,883,156     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,889,136     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,895,009     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,906,372     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,906,373     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,906,646     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,911,737     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,911,964     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,916,153     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,926,975     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,961,973     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,961,974     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,974,790     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,986,693     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,992,926     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 8,999,337     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,061,005     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,062,106     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,067,992     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,085,618     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,085,619     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,085,620     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,090,688     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,090,689     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,090,867     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,096,666     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,102,723     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,150,645     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,181,337     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,181,572     |        |
| 125057     | AbbVie Inc.    | Humira           | adalimumab    | 9,187,559     |        |

<https://purplebooksearch.fda.gov/patent-list>

| BLA Number | Applicant Name  | Proprietary Name | Proper Name | Patent Number | Patent |
|------------|-----------------|------------------|-------------|---------------|--------|
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,234,032     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,266,949     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,273,132     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,284,370     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,284,371     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,290,568     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,315,574     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,328,165     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,334,319     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,339,610     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,346,879     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,359,434     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,499,614     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,499,616     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,505,834     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,512,216     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,522,953     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,546,212     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,550,826     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,624,295     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,669,093     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,683,033     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,708,400     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,913,902     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 9,957,318     |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 11,083,792    |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 11,167,030    |        |
| 125057     | AbbVie Inc.     | Humira           | adalimumab  | 11,191,834    |        |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 10,906,986    | 2028-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 7,485,704     | 2025-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 8,460,895     | 2029-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 8,512,983     | 2031-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 8,574,869     | 2028-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 9,441,035     | 2034-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 9,487,809     | 2032-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 9,714,293     | 2030-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 9,795,672     | 2024-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 10,011,856    | 2031-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 10,017,732    | 2034-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 10,208,355    | 2035-  |
| 125085     | Genentech, Inc. | Avastin          | bevacizumab | 10,274,466    | 2035-  |

<https://purplebooksearch.fda.gov/patent-list>

| BLA Number | Applicant Name                  | Proprietary Name | Proper Name | Patent Number | Patent   |
|------------|---------------------------------|------------------|-------------|---------------|----------|
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 10,336,983    | 2035-    |
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 10,513,697    | 2032-    |
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 10,662,237    | 2031-    |
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 10,676,710    | 2034-    |
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 10,704,071    | 2031-    |
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 10,829,732    | 2034-    |
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 10,906,934    | 2033-    |
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 10,982,003    |          |
| 125085     | Genentech, Inc.                 | Avastin          | bevacizumab | 11,078,294    |          |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 6,716,602     | 2021-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 6,828,121     | 2022-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 6,921,659     | 2023-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 8,574,869     | 2028-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 9,765,379     | 2034-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 10,017,732    | 2034-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 10,112,994    | 2035-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 10,421,984    | 2033-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 10,829,732    | 2034-    |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 8,383,773     |          |
| 125156     | Genentech, Inc.                 | Lucentis         | ranibizumab | 9,688,775     |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 7,070,959     |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 9,222,106     |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 9,254,338     |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 9,669,069     |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 9,816,110     |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,130,681    |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | D858,754      | S        |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,406,226    |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,415,055    |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,464,992    |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,669,594    | F        |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,828,345    | J        |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,857,205    | J        |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,857,231    | Disclaim |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | D906,102      | D        |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,888,601    | J        |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,905,786    |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,918,754    |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,927,342    |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 10,973,879    |          |
| 125387     | Regeneron Pharmaceuticals, Inc. | Eylea            | aflibercept | 11,053,280    |          |

<https://purplebooksearch.fda.gov/patent-list>

| <b>BLA Number</b> | <b>Applicant Name</b>           | <b>Proprietary Name</b> | <b>Proper Name</b> | <b>Patent Number</b> | <b>Patent</b> |
|-------------------|---------------------------------|-------------------------|--------------------|----------------------|---------------|
| 125387            | Regeneron Pharmaceuticals, Inc. | Eylea                   | aflibercept        | 11,066,458           |               |
| 125387            | Regeneron Pharmaceuticals, Inc. | Eylea                   | aflibercept        | 11,084,865           |               |
| 125387            | Regeneron Pharmaceuticals, Inc. | Eylea                   | aflibercept        | 11,104,715           |               |
| 125387            | Regeneron Pharmaceuticals, Inc. | Eylea                   | aflibercept        | D934,069             |               |
| 125387            | Regeneron Pharmaceuticals, Inc. | Eylea                   | aflibercept        | 11,160,918           |               |
| 125387            | Regeneron Pharmaceuticals, Inc. | Eylea                   | aflibercept        | 11,174,283           |               |
| 125387            | Regeneron Pharmaceuticals, Inc. | Eylea                   | aflibercept        | 11,186,625           |               |
| 125387            | Regeneron Pharmaceuticals, Inc. | Eylea                   | aflibercept        | 11,253,572           |               |

<https://purplebooksearch.fda.gov/patent-list>